Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations
JCI Insight · 08.11.2023 · 8 (21)
DOI: 10.1172/jci.insight.173095 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JCI Insight, online erschienen am 08.11.2023. Verfasst von Emmanuel Seront und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Vascular Anomalies, Cliniques universitaires Saint-Luc, University of Louvain, VASCERN VASCA European Reference Centre, Brussels, Belgium. Hauptthemen laut MEDLINE: Sirolimus, Vascular Malformations. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds De La Recherche Scientifique - FNRS, Fund Generet managed by the King Baudouin Foundation, FRFS-WELBIO.
Abstract (Originalsprache)
BACKGROUND Slow-flow vascular malformations frequently harbor activating mutations in the PI3K/AKT/mTOR cascade. Phase II trials pinpointed sirolimus effectiveness as a drug therapy. Efficacy and safety of sirolimus thus need to be evaluated in large prospective phase III trials. METHODS The Vascular Anomaly-Sirolimus-Europe (VASE) trial, initiated in 2016, is a large multicentric prospective phase III trial (EudraCT 2015-001703-32), which evaluates efficacy and safety of sirolimus for 2 years in pediatric and adult patients with symptomatic slow-flow vascular malformations. In this interim analysis, we studied all patients enrolled up to October 2021 who received sirolimus for 12 or more months or who prematurely stopped the treatment. RESULTS Thirty-one pediatric and 101 adult patients were included in this analysis; 107 completed 12 or more months of sirolimus, including 61 who were treated for the whole 2-year period. Sirolimus resulted in a clinical improvement in 85% of patients. The efficacy appeared within the first month for the majority of them. Grade 3–4 adverse events were observed in 24 (18%) patients; all resolved after treatment interruption/arrest. Sirolimus increased feasibility of surgery or sclerotherapy in 20 (15%) patients initially deemed unsuitable for intervention. Among the 61 patients who completed the 2-year treatment, 33 (54%) reported a recurrence of symptoms after a median follow-up of 13 months after sirolimus arrest. While there was no difference in efficacy, clinical improvement was faster but subsided more rapidly in PIK3CA -mutated ( n = 24 ) compared with TIE2 -mutated ( n = 19) patients. CONCLUSION Sirolimus has a high efficacy and good tolerance in treatment of slow-flow vascular malformations in children and adults. TRIAL REGISTRATION ClinicalTrials.gov NCT02638389 and EudraCT 2015-001703-32. FUNDING The Fonds de la Recherche Scientifique (FNRS grants T.0247.19, P.C005.22, T.0146.16, and P.C013.20), the Fund Generet managed by the King Baudouin Foundation (grant 2018-J1810250-211305), the Walloon Region through the FRFS-WELBIO strategic research programme (WELBIO-CR-2019C-06), the MSCA-ITN network V.A. Cure no. 814316, the Leducq Foundation Networks of Excellence Program grant “ReVAMP” (LFCR grant 21CVD03), the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 874708 (Theralymph), the Swiss National Science Foundation under the Sinergia project no. CRSII5_193694, and a Pierre M. fellowship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Vascular Anomalies, Cliniques universitaires Saint-Luc, University of Louvain, VASCERN VASCA European Reference Centre, Brussels, Belgium.
- Institut Roi Albert II, Department of Medical Oncology, and.
- Institut Roi Albert II, Department of Pediatric Hematology & Oncology, Cliniques universitaires Saint-Luc, University of Louvain, Brussels, Belgium.
- ISBA/LIDAM, UCLouvain, Louvain-la-Neuve, Belgium.
- Neuroradiology Department of Pr Houdart Lariboisière Hospital, Center of vascular anomalies clinic VASCERN VASCA European Reference Centre, Paris, France.
- Department of Rheumatology - DMU Locomotion, AP-HP Nord - University of Paris and INSERM U1132 BIOSCAR, Paris, France, Paris, France.
Förderung
- Fonds De La Recherche Scientifique - FNRS
- Fund Generet managed by the King Baudouin Foundation
- FRFS-WELBIO
- MSCA-ITN network V.A. Cure
- Leducq Foundation Networks of Excellence Program grant “ReVAMP” - European Union’s Horizon 2020 research and innovation programme
- Swiss National Science Foundation under the Sinergia project
Zitieren
APA
Seront, E., Van Damme, A., Legrand, C., Bisdorff-Bresson, A., Orcel, P., Funck-Brentano, T., Sevestre, M. A., Dompmartin, A., Quere, I., Brouillard, P., Revencu, N., De Bortoli, M., Hammer, F., Clapuyt, P., Dumitriu, D., Vikkula, M., & Boon, L. M. (2023). Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. JCI Insight, 8(21). https://doi.org/10.1172/jci.insight.173095
Vancouver
Seront E, Van Damme A, Legrand C, Bisdorff-Bresson A, Orcel P, Funck-Brentano T, et al. Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations. JCI Insight. 2023;8(21). doi:10.1172/jci.insight.173095
BibTeX
@article{Seront2023,
author = {Seront, Emmanuel and Van Damme, An and Legrand, Catherine and Bisdorff-Bresson, Annouk and Orcel, Philippe and Funck-Brentano, Thomas and Sevestre, Marie-Antoinette and Dompmartin, Anne and Quere, Isabelle and Brouillard, Pascal and Revencu, Nicole and De Bortoli, Martina and Hammer, Frank and Clapuyt, Philippe and Dumitriu, Dana and Vikkula, Miikka and Boon, Laurence M},
title = {Preliminary results of the European multicentric phase III trial regarding sirolimus in slow-flow vascular malformations},
journal = {JCI Insight},
year = {2023},
volume = {8},
number = {21},
doi = {10.1172/jci.insight.173095}
}
EUVIMED